CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
Onconetix extends up to $5 million in bridge financing to Realbotix, easing closing cash needs if their all-stock acquisition is completed.
Rhea-AI Summary
Onconetix (ONCO) has provided Realbotix LLC with a non-interest-bearing bridge financing facility of up to $5,000,000 while their pending acquisition progresses toward closing.
The facility allows an aggregate principal of up to $5,000,000, including an initial advance of $2,500,000 to support Realbotix's growth and working capital needs. The financing is tied to the Share Exchange Agreement announced on February 12, 2026, under which Onconetix plans to acquire 100% of Realbotix in an all-stock transaction. Upon closing, the note and all related obligations are automatically cancelled, and the cash required at closing is reduced by the total principal advanced plus an additional $500,000. If the Share Exchange Agreement is terminated, interest on the outstanding amount accrues at 12% per annum from the termination date. The combined company is expected to trade on Nasdaq after closing, which remains subject to shareholder and regulatory approvals and other conditions.
Positive
- Bridge facility up to $5,000,000 supports Realbotix growth and working capital before closing
- Initial advance of $2,500,000 already provided under the non-interest-bearing facility
- Cash at closing reduced by total principal advanced plus an additional $500,000 if the acquisition closes
- Facility cancelled at closing, eliminating the related obligations once the Share Exchange Agreement is completed
Negative
- 12% annual interest applies to the outstanding amount if the Share Exchange Agreement is terminated
- Acquisition closing remains uncertain, subject to shareholder approval, regulatory approvals, and other conditions
News Explained
The
Sources and calculations
- Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition (2026-09-14)
- Onconetix latest-quarter fundamentals (2026Q2)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $5,942,249 / ($1,918,067 / 91) = 281.9 days
Details
Market Reaction – ONCO
Following this news, ONCO has declined 14.36%, reflecting a significant negative market reaction. Our momentum scanner has triggered 33 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.65. Trading volume is very high at 3.6x the average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Bridge facility
- $5,000,000
- Aggregate principal amount available to Realbotix
- Initial advance
- $2,500,000
- Funded under the bridge financing facility
- Closing cash reduction
- $500,000
- Additional reduction in cash required at acquisition closing
- Termination interest rate
- 12% per annum
- Applies if the Share Exchange Agreement is terminated
- Acquisition ownership
- 100%
- Realbotix LLC equity interests to be acquired in the all-stock transaction
Previous Acquisition Reports
-
Realbotix launched a telecommunications pilot for humanoid robot deployments in live events.
-
Realbotix agreed to feature a humanoid robot on an Emmy-winning streaming series.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
bridge financing facility financial
all-stock transaction financial
form 8-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Initial Advance of
CINCINNATI, Ohio, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the "Company") today announced that it has provided a strategic bridge financing facility of up to
The facility provides for an aggregate principal amount of up to
The facility is non-interest bearing prior to the closing of the Share Exchange Agreement. Upon closing of the acquisition, the facility and all obligations thereunder will be automatically cancelled and discharged in full. In addition, the cash required at closing of the acquisitions will be reduced by the total principal advanced under the facility plus an additional
As previously announced on February 12, 2026, Onconetix entered into the Share Exchange Agreement to acquire
This communication is being provided for informational purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected information.
About Onconetix, Inc.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.
About Realbotix LLC
Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States, Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement. For more information, visit www.realbotix.ai.
Additional Information and Where to Find It
In connection with the proposed transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND RELATED MATTERS.
A copy of the Registration Statement, Proxy Statement/Prospectus, as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov. The information on Realbotix or Onconetix’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
Participants in the Solicitation
Realbotix, Onconetix and certain of their respective directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s transactions with related persons is set forth in the 10-K, as filed with the SEC on March 13, 2026, and other documents that may be filed from time to time with the SEC. Additional information about the directors and executive officers of Realbotix and Onconetix and other persons who may be deemed to be participants in the solicitation of stockholders of Onconetix in connection with the proposed transaction and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will be filed with the SEC. These documents may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov and from Onconetix using the sources indicated above.
No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the anticipated benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s stockholders, if at all; risks related to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that may be instituted against Realbotix, Onconetix, or the combined company; the possibility that the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events; the diversion of management’s attention from ongoing business operations and opportunities; changes in Onconetix’s stock price before closing; and other factors that may affect future results of Realbotix, Onconetix, or the combined company. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor and Media Contact:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Email: investors@onconetix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much has Onconetix advanced to Realbotix so far under the bridge facility?
Under the bridge financing facility, Onconetix has made an initial advance of $2,500,000 to Realbotix. The total facility size is up to $5,000,000.
What happens to the bridge financing if the Realbotix acquisition closes?
Upon closing of the acquisition under the Share Exchange Agreement, the facility and all obligations under it are automatically cancelled and discharged in full, and the cash required at closing is reduced by the total principal advanced plus an additional $500,000.
Where can investors find the full terms of the bridge note?
A description of the note is included in Onconetix’s Current Report on Form 8-K filed with the SEC on September 14, 2026, and the full text is filed as an exhibit to that report and is available at www.sec.gov.